On World Diabetes Day, it's worth taking a look back at the last 10.5 months in the diabetes technology space.

Insulet’s Omnipod 5 automated insulin delivery (AID) system has multiple avenues to expand as it has revolutionized the way patients treat their diabetes, including the new indication for Type 2 ...

Kamen and Sequel Medtech CEO Alan Lotvin say they are offering greater precision in insulin delivery with new pump technology ...

Insulet (Nasdaq:PODD) shares ticked up today on third-quarter results that came in well ahead of the consensus forecast.

Insulet saw strong insulin pump adoption among new users with Type 2 diabetes following its recent FDA clearance, while ...

The company now expects its annual 2024 revenue to grow between 20% and 21%, up from its previous forecast of 16% to 19% ...

Insulet ( (PODD) ) has released its Q3 earnings. Here is a breakdown of the information Insulet presented to its investors. Insulet ...

From wearable glucose monitors to AI-driven health insights, recent advances are giving patients new ways to manage blood ...

Reports Q3 revenue $543.9M, consensus $518.26M. “We continue to achieve significant milestones and robust revenue growth,” said Jim ...

CNW/ - Ypsomed and CamDiab are pleased to announce the approval of mylife YpsoPump insulin pump and CamAPS FX hybrid closed-loop algorithm by Health Canada. This approval represents an important step ...

Insulet produces and sells Omnipod, an automated insulin delivery device ... making it the first such system to be cleared for use in both type 1 and type 2 diabetes. In September, the company ...

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes.